Literature DB >> 11556812

Heterologous expression of cytochrome P450 2D6 mutants, electron transfer, and catalysis of bufuralol hydroxylation: the role of aspartate 301 in structural integrity.

I H Hanna1, M S Kim, F P Guengerich.   

Abstract

Cytochrome P450 (P450) 2D6 is a polymorphic human enzyme involved in the oxidation of >50 drugs, most of which contain a basic nitrogen. In confirmation of previous work by others, substitutions at Asp301 decreased rates of substrate oxidation by P450 2D6. An anionic residue (Asp, Glu) at this position was found to be important in proper protein folding and heme incorporation, and positively charged residues were particularly disruptive in bacterial and also in baculovirus expression systems. Truncation of 20 N-terminal amino acids had no significant effect on catalytic activity except to attenuate P450 2D6 interaction with membranes and NADPH-P450 reductase. The truncation of the N-terminus increased the level of bacterial expression of wild-type P450 2D6 (Asp301) but markedly reduced expression of all codon 301 mutants, including Glu301. Reduction of ferric P450 2D6 by NADPH-P450 reductase was enhanced in the presence of the prototypic substrate bufuralol. Bacterial flavodoxin, an NADPH-P450 reductase homolog, binds tightly to P450 2D6 but is inefficient in electron transfer to the heme. These results collectively indicate that the acidic residue at position 301 in P450 2D6 has a structural role in addition to any in substrate binding and that the N-terminus of P450 2D6 is relatively unimportant to catalytic activity beyond a role in facilitating binding to NADPH-P450 reductase. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11556812     DOI: 10.1006/abbi.2001.2510

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  20 in total

1.  Crystal structure of human cytochrome P450 2D6 with prinomastat bound.

Authors:  An Wang; Uzen Savas; Mei-Hui Hsu; C David Stout; Eric F Johnson
Journal:  J Biol Chem       Date:  2012-02-03       Impact factor: 5.157

2.  Anandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6.

Authors:  Chitra Sridar; Natasha T Snider; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2011-02-02       Impact factor: 3.922

3.  Human liver mitochondrial cytochrome P450 2D6--individual variations and implications in drug metabolism.

Authors:  Michelle Cook Sangar; Hindupur K Anandatheerthavarada; Weigang Tang; Subbuswamy K Prabu; Martha V Martin; Miroslav Dostalek; F Peter Guengerich; Narayan G Avadhani
Journal:  FEBS J       Date:  2009-05-11       Impact factor: 5.542

4.  Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6.

Authors:  Mara R Livezey; Erran D Briggs; Amanda K Bolles; Leslie D Nagy; Rina Fujiwara; Laura Lowe Furge
Journal:  Xenobiotica       Date:  2013-09-06       Impact factor: 1.908

5.  Role of conserved Asp293 of cytochrome P450 2C9 in substrate recognition and catalytic activity.

Authors:  Jack U Flanagan; Lesley A McLaughlin; Mark J I Paine; Michael J Sutcliffe; Gordon C K Roberts; C Roland Wolf
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

6.  Aromatic hydroxylation of salicylic acid and aspirin by human cytochromes P450.

Authors:  Mirza Bojić; Carl A Sedgeman; Leslie D Nagy; F Peter Guengerich
Journal:  Eur J Pharm Sci       Date:  2015-03-31       Impact factor: 4.384

7.  Nitric oxide blocks cellular heme insertion into a broad range of heme proteins.

Authors:  Syed Mohsin Waheed; Arnab Ghosh; Ritu Chakravarti; Ashis Biswas; Mohammad Mahfuzul Haque; Koustubh Panda; Dennis J Stuehr
Journal:  Free Radic Biol Med       Date:  2010-03-06       Impact factor: 7.376

8.  Metabolism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by mitochondrion-targeted cytochrome P450 2D6: implications in Parkinson disease.

Authors:  Prachi Bajpai; Michelle C Sangar; Shilpee Singh; Weigang Tang; Seema Bansal; Goutam Chowdhury; Qian Cheng; Ji-Kang Fang; Martha V Martin; F Peter Guengerich; Narayan G Avadhani
Journal:  J Biol Chem       Date:  2012-12-20       Impact factor: 5.157

9.  Sulfenylation of Human Liver and Kidney Microsomal Cytochromes P450 and Other Drug-Metabolizing Enzymes as a Response to Redox Alteration.

Authors:  Matthew E Albertolle; Thanh T N Phan; Ambra Pozzi; F Peter Guengerich
Journal:  Mol Cell Proteomics       Date:  2018-01-26       Impact factor: 5.911

10.  The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6.

Authors:  Natasha T Snider; Matthew J Sikora; Chitra Sridar; Thomas J Feuerstein; James M Rae; Paul F Hollenberg
Journal:  J Pharmacol Exp Ther       Date:  2008-08-12       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.